JAGX Quote, Financials, Valuation and Earnings

Geron Corp. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of -39.02%. Jaguar Health, Inc.'s return on equity of -524.57% beat Geron Corp.'s return on equity of -29.65%.

Jaguar Health, Inc. has a consensus price target of $25.50, signalling upside risk potential of 3680.02%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 162.77%. Given that Jaguar Health, Inc. has higher upside potential than Geron Corp., analysts believe Jaguar Health, Inc. is more attractive than Geron Corp..

Jaguar Health, Inc. has a beta of -0.422, which suggesting that the stock is 142.19% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.567%.

Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.

Jaguar Health, Inc. quarterly revenues are $3.1M, which are smaller than Geron Corp. quarterly revenues of $47.2M. Jaguar Health, Inc.'s net income of -$9.6M is higher than Geron Corp.'s net income of -$18.4M. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.23x versus 4.97x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of -316.61%. Jaguar Health, Inc.'s return on equity of -524.57% beat Plus Therapeutics, Inc.'s return on equity of --.

Jaguar Health, Inc. has a consensus price target of $25.50, signalling upside risk potential of 3680.02%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $6.38 which suggests that it could grow by 2694.83%. Given that Jaguar Health, Inc. has higher upside potential than Plus Therapeutics, Inc., analysts believe Jaguar Health, Inc. is more attractive than Plus Therapeutics, Inc..

Jaguar Health, Inc. has a beta of -0.422, which suggesting that the stock is 142.19% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.845, suggesting its less volatile than the S&P 500 by 15.456%.

Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Jaguar Health, Inc. quarterly revenues are $3.1M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Jaguar Health, Inc.'s net income of -$9.6M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.23x versus 3.66x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rapt Therapeutics, Inc. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of --. Jaguar Health, Inc.'s return on equity of -524.57% beat Rapt Therapeutics, Inc.'s return on equity of -67.79%.

Jaguar Health, Inc. has a consensus price target of $25.50, signalling upside risk potential of 3680.02%. On the other hand Rapt Therapeutics, Inc. has an analysts' consensus of $57.67 which suggests that it could fall by -0.02%. Given that Jaguar Health, Inc. has higher upside potential than Rapt Therapeutics, Inc., analysts believe Jaguar Health, Inc. is more attractive than Rapt Therapeutics, Inc..

Jaguar Health, Inc. has a beta of -0.422, which suggesting that the stock is 142.19% less volatile than S&P 500. In comparison Rapt Therapeutics, Inc. has a beta of 0.455, suggesting its less volatile than the S&P 500 by 54.461%.

Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rapt Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Rapt Therapeutics, Inc. pays out -- of its earnings as a dividend.

Jaguar Health, Inc. quarterly revenues are $3.1M, which are larger than Rapt Therapeutics, Inc. quarterly revenues of --. Jaguar Health, Inc.'s net income of -$9.6M is higher than Rapt Therapeutics, Inc.'s net income of -$17.6M. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Rapt Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.23x versus 54.16x for Rapt Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of -3135.32%. Jaguar Health, Inc.'s return on equity of -524.57% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Jaguar Health, Inc. has a consensus price target of $25.50, signalling upside risk potential of 3680.02%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 67.06%. Given that Jaguar Health, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Jaguar Health, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

Jaguar Health, Inc. has a beta of -0.422, which suggesting that the stock is 142.19% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Jaguar Health, Inc. quarterly revenues are $3.1M, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Jaguar Health, Inc.'s net income of -$9.6M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.23x versus 38.44x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.